{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T01:18:12Z","timestamp":1787879892947,"version":"build-2784847793"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":71,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004772","name":"Ningxia Natural Science Foundation","doi-asserted-by":"crossref","award":["2023AAC05061"],"award-info":[{"award-number":["2023AAC05061"]}],"id":[{"id":"10.13039\/501100004772","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["12275003"],"award-info":[{"award-number":["12275003"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"DOI":"10.1007\/s00432-026-06537-2","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T14:41:10Z","timestamp":1781793670000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Synthesis of Gd-DOTA-BMTP and its application in gadolinium neutron capture therapy for osteosarcoma"],"prefix":"10.1007","volume":"152","author":[{"given":"Aoyun","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bowen","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxi","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JiaLin","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ni","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"6537_CR1","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.7150\/thno.30030","volume":"9","author":"J Abello","year":"2019","unstructured":"Abello J, Nguyen T, Marasini R, Aryal S, Weiss M (2019) Biodistribution of gadolinium- and near infrared-labeled human umbilical cord mesenchymal stromal cell-derived exosomes in tumor bearing mice. Theranostics 9:2325\u20132345. https:\/\/doi.org\/10.7150\/thno.30030","journal-title":"Theranostics"},{"key":"6537_CR2","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.addr.2007.06.008","volume":"59","author":"L Bareford","year":"2007","unstructured":"Bareford L, Swaan P (2007) Endocytic mechanisms for targeted drug delivery\u2606. Adv Drug Deliv Rev 59:748\u2013758. https:\/\/doi.org\/10.1016\/j.addr.2007.06.008","journal-title":"Adv Drug Deliv Rev"},{"key":"6537_CR3","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/1748-717X-7-146","volume":"7","author":"RF Barth","year":"2012","unstructured":"Barth RF, Vicente H, Harling OK et al (2012) Current status of boron neutron capture therapy of high grade gliomas and recurrent head and neck cancer. Radiat Oncol 7:146. https:\/\/doi.org\/10.1186\/1748-717X-7-146","journal-title":"Radiat Oncol"},{"key":"6537_CR4","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s40880-018-0280-5","volume":"38","author":"RF Barth","year":"2018","unstructured":"Barth RF, Zhang Z, Liu T (2018a) A realistic appraisal of boron neutron capture therapy as a cancer treatment modality. Cancer Commun 38:36. https:\/\/doi.org\/10.1186\/s40880-018-0280-5","journal-title":"Cancer Commun"},{"key":"6537_CR5","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s40880-018-0299-7","volume":"38","author":"RF Barth","year":"2018","unstructured":"Barth RF, Mi P, Yang W (2018b) Boron delivery agents for neutron capture therapy of cancer. Cancer Commun (Lond) 38:35. https:\/\/doi.org\/10.1186\/s40880-018-0299-7","journal-title":"Cancer Commun (Lond)"},{"key":"6537_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-022-00409-y","volume":"8","author":"H Beird","year":"2022","unstructured":"Beird H, Bielack S, Flanagan A et al (2022) Osteosarcoma. Nat Rev Dis Primers 8:1\u201319. https:\/\/doi.org\/10.1038\/s41572-022-00409-y","journal-title":"Nat Rev Dis Primers"},{"key":"6537_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2025.115550","volume":"219","author":"IB Belyaev","year":"2025","unstructured":"Belyaev IB, Griaznova OY, Yaremenko AV, Deyev SM, Zelepukin IV (2025) Beyond the EPR effect: Intravital microscopy analysis of nanoparticle drug delivery to tumors. Adv Drug Deliv Rev 219:115550. https:\/\/doi.org\/10.1016\/j.addr.2025.115550","journal-title":"Adv Drug Deliv Rev"},{"key":"6537_CR8","doi-asserted-by":"publisher","first-page":"899","DOI":"10.4155\/fmc-2016-0022","volume":"8","author":"A Deagostino","year":"2016","unstructured":"Deagostino A, Protti N, Alberti D, Boggio P, Bortolussi S, Altieri S, Crich SG (2016) Insights into the use of gadolinium and gadolinium\/boron-based agents in imaging-guided neutron capture therapy applications. Future Med Chem 8:899\u2013917. https:\/\/doi.org\/10.4155\/fmc-2016-0022","journal-title":"Future Med Chem"},{"key":"6537_CR9","doi-asserted-by":"publisher","DOI":"10.1093\/ptep\/ptz002","author":"K Hagiwara","year":"2019","unstructured":"Hagiwara K, Yano T, Tanaka T et al (2019) Gamma-ray spectrum from thermal neutron capture on gadolinium-157. Prog Theor Exp Phys. https:\/\/doi.org\/10.1093\/ptep\/ptz002","journal-title":"Prog Theor Exp Phys"},{"key":"6537_CR10","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/s13014-021-01939-7","volume":"16","author":"H He","year":"2021","unstructured":"He H, Li J, Jiang P et al (2021) The basis and advances in clinical application of boron neutron capture therapy. Radiat Oncol 16:216. https:\/\/doi.org\/10.1186\/s13014-021-01939-7","journal-title":"Radiat Oncol"},{"key":"6537_CR11","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1039\/C9RA08961F","volume":"10","author":"SL Ho","year":"2020","unstructured":"Ho SL, Choi G, Yue H et al (2020) In vivo neutron capture therapy of cancer using ultrasmall gadolinium oxide nanoparticles with cancer-targeting ability. RSC Adv 10:865\u2013874. https:\/\/doi.org\/10.1039\/C9RA08961F","journal-title":"RSC Adv"},{"key":"6537_CR12","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1021\/acsomega.1c06603","volume":"7","author":"SL Ho","year":"2022","unstructured":"Ho SL, Yue H, Tegafaw T et al (2022) Gadolinium neutron capture therapy (GdNCT) agents from molecular to nano: current status and perspectives. ACS Omega 7:2533\u20132553. https:\/\/doi.org\/10.1021\/acsomega.1c06603","journal-title":"ACS Omega"},{"key":"6537_CR13","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1158\/0008-5472.Can-11-2778","volume":"72","author":"G Huang","year":"2012","unstructured":"Huang G, Yu L, Cooper LJN, Hollomon M, Huls H, Kleinerman ES (2012) Genetically modified T cells targeting interleukin-11 receptor \u03b1-chain kill human osteosarcoma cells and induce the regression of established osteosarcoma lung metastases. Can Res 72:271\u2013281. https:\/\/doi.org\/10.1158\/0008-5472.Can-11-2778","journal-title":"Can Res"},{"key":"6537_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2019.100230","author":"X Huang","year":"2019","unstructured":"Huang X, Zhao J, Bai et al (2019) Risk and clinicopathological features of osteosarcoma metastasis to the lung: a population-based study. J Bone Oncol. https:\/\/doi.org\/10.1016\/j.jbo.2019.100230","journal-title":"J Bone Oncol"},{"key":"6537_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics15030266","author":"A Ivan","year":"2025","unstructured":"Ivan A, Cojocaru E, Sirbu et al (2025) Clinical and pathological profile of children and adolescents with osteosarcoma. Diagnostics. https:\/\/doi.org\/10.3390\/diagnostics15030266","journal-title":"Diagnostics"},{"key":"6537_CR16","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.jconrel.2022.08.048","volume":"350","author":"J Jiang","year":"2022","unstructured":"Jiang J, Wang R, Yang L et al (2022) IL-11R\u03b1-targeted nanostrategy empowers chemotherapy of relapsed and patient-derived osteosarcoma. J Control Release 350:460\u2013470. https:\/\/doi.org\/10.1016\/j.jconrel.2022.08.048","journal-title":"J Control Release"},{"key":"6537_CR17","doi-asserted-by":"publisher","first-page":"71","DOI":"10.14338\/ijpt-22-00002.1","volume":"9","author":"W Jin","year":"2022","unstructured":"Jin W, Seldon C, Butkus M, Sauerwein W, Giap H (2022) A review of boron neutron capture therapy: its history and current challenges. Int J Part Ther 9:71\u201382. https:\/\/doi.org\/10.14338\/ijpt-22-00002.1","journal-title":"Int J Part Ther"},{"key":"6537_CR18","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s00234-019-02172-6","volume":"61","author":"A Kiviniemi","year":"2019","unstructured":"Kiviniemi A, Gardberg M, Ek P, Frantz\u00e9n J, Bobacka J, Minn H (2019) Gadolinium retention in gliomas and adjacent normal brain tissue: association with tumor contrast enhancement and linear\/macrocyclic agents. Neuroradiology 61:535\u2013544. https:\/\/doi.org\/10.1007\/s00234-019-02172-6","journal-title":"Neuroradiology"},{"key":"6537_CR19","doi-asserted-by":"publisher","first-page":"13360","DOI":"10.1038\/s41598-022-17610-4","volume":"12","author":"W Lee","year":"2022","unstructured":"Lee W, Kim KW, Lim JE, Sarkar S, Kim JY, Chang Y, Yoo J (2022) In vivo evaluation of the effects of combined boron and gadolinium neutron capture therapy in mouse models. Sci Rep 12:13360. https:\/\/doi.org\/10.1038\/s41598-022-17610-4","journal-title":"Sci Rep"},{"key":"6537_CR20","doi-asserted-by":"publisher","unstructured":"Lewis VO (2014) IL-11R\u03b1: a novel target for the treatment of osteosarcoma. In: Kleinerman MDES (ed) Current advances in osteosarcoma. Springer International Publishing, Cham. https:\/\/doi.org\/10.1007\/978-3-319-04843-7_15","DOI":"10.1007\/978-3-319-04843-7_15"},{"key":"6537_CR21","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1158\/0008-5472.Can-08-4845","volume":"69","author":"VO Lewis","year":"2009","unstructured":"Lewis VO, Ozawa MG, Deavers MT, Wang G, Shintani T, Arap W, Pasqualini R (2009) The interleukin-11 receptor \u03b1 as a candidate ligand-directed target in osteosarcoma: consistent data from cell lines, orthotopic models, and human tumor samples. Can Res 69:1995\u20131999. https:\/\/doi.org\/10.1158\/0008-5472.Can-08-4845","journal-title":"Can Res"},{"key":"6537_CR22","doi-asserted-by":"publisher","first-page":"8065","DOI":"10.1073\/pnas.1704173114","volume":"114","author":"VO Lewis","year":"2017","unstructured":"Lewis VO, Devarajan E, Card\u00f3-Vila M et al (2017) BMTP-11 is active in preclinical models of human osteosarcoma and a candidate targeted drug for clinical translation. Proc Natl Acad Sci 114:8065\u20138070. https:\/\/doi.org\/10.1073\/pnas.1704173114","journal-title":"Proc Natl Acad Sci"},{"key":"6537_CR23","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s00292-020-00756-1","volume":"41","author":"J Lokau","year":"2020","unstructured":"Lokau J, Schoeder V, Garbers C (2020) Die Rolle von Interleukin-11 beim Osteosarkom. Pathologe 41:163\u2013167. https:\/\/doi.org\/10.1007\/s00292-020-00756-1","journal-title":"Pathologe"},{"key":"6537_CR24","doi-asserted-by":"publisher","DOI":"10.1021\/acsami.5c05524","author":"M Luo","year":"2025","unstructured":"Luo M, Bailey M, Kim H, Lei Y, Meade T (2025) Alkaline phosphatase-targeted, gadolinium-labeled nanoparticles for enhanced multimodal imaging of liver cancer. ACS Appl Mater Interfaces. https:\/\/doi.org\/10.1021\/acsami.5c05524","journal-title":"ACS Appl Mater Interfaces"},{"key":"6537_CR25","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3390\/genes14010127","volume":"14","author":"GV Mechetin","year":"2023","unstructured":"Mechetin GV, Zharkov DO (2023) DNA damage response and repair in boron neutron capture therapy. Genes 14:127.https:\/\/doi.org\/10.3390\/genes14010127","journal-title":"Genes"},{"key":"6537_CR26","doi-asserted-by":"publisher","first-page":"361","DOI":"10.2176\/nmc.ra.2015-0297","volume":"56","author":"S Miyatake","year":"2016","unstructured":"Miyatake S, Kawabata S, Hiramatsu R, Kuroiwa T, Suzuki M, Kondo N, Ono K (2016) Boron neutron capture therapy for malignant brain tumors. Neurol Med Chir 56:361\u2013371. https:\/\/doi.org\/10.2176\/nmc.ra.2015-0297","journal-title":"Neurol Med Chir"},{"key":"6537_CR27","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.3390\/cancers14143503","volume":"14","author":"B Moukengue","year":"2022","unstructured":"Moukengue B, Lallier M, Marchandet L, Verrecchia F, Ory B, Lamoureux F (2022) Origin and therapies of osteosarcoma. Cancers (Basel) 14:3503.https:\/\/doi.org\/10.3390\/cancers14143503","journal-title":"Cancers (Basel)"},{"key":"6537_CR28","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aaz1722","volume":"6","author":"T Nomoto","year":"2020","unstructured":"Nomoto T, Inoue Y, Yao Y et al (2020) Poly(vinyl alcohol) boosting therapeutic potential of p-boronophenylalanine in neutron capture therapy by modulating metabolism. Sci Adv 6:eaaz1722. https:\/\/doi.org\/10.1126\/sciadv.aaz1722","journal-title":"Sci Adv"},{"key":"6537_CR29","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1007\/s11914-023-00803-9","volume":"21","author":"I Panez-Toro","year":"2023","unstructured":"Panez-Toro I, Mu\u00f1oz-Garc\u00eda J, Vargas-Franco J, Renodon-Corni\u00e8re A, Heymann M, L\u00e9zot F, Heymann D (2023) Advances in osteosarcoma. Curr Osteoporos Rep 21:330\u2013343. https:\/\/doi.org\/10.1007\/s11914-023-00803-9","journal-title":"Curr Osteoporos Rep"},{"key":"6537_CR30","unstructured":"Rodriguez-Lafrasse C, Aloy M-T, Boumedine JS et al (2017) AGuIX radiosensitizing nanoparticles: from molecular events to clinical applications. In: 63rd annual international meeting of Radiation Reaserach Society,"},{"key":"6537_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/acm2.14399","volume":"25","author":"R Shamsabadi","year":"2024","unstructured":"Shamsabadi R, Baghani HR (2024) DNA-damage RBE assessment for combined boron and gadolinium neutron capture therapy. J Appl Clin Med Phys 25:e14399. https:\/\/doi.org\/10.1002\/acm2.14399","journal-title":"J Appl Clin Med Phys"},{"key":"6537_CR32","doi-asserted-by":"publisher","first-page":"7921","DOI":"10.7150\/thno.49577","volume":"10","author":"Y Shi","year":"2020","unstructured":"Shi Y, van der Meel R, Chen X, Lammers T (2020) The EPR effect and beyond: strategies to improve tumor targeting and cancer nanomedicine treatment efficacy. Theranostics 10:7921\u20137924. https:\/\/doi.org\/10.7150\/thno.49577","journal-title":"Theranostics"},{"key":"6537_CR33","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1118\/1.596817","volume":"19","author":"JLA Shih","year":"1992","unstructured":"Shih JLA, Brugger RM (1992) Gadolinium as a neutron capture therapy agent. Med Phys 19:733\u2013744.https:\/\/doi.org\/10.1118\/1.596817","journal-title":"Med Phys"},{"key":"6537_CR34","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ejca.2018.11.027","volume":"109","author":"S Smeland","year":"2019","unstructured":"Smeland S, Bielack S, Whelan J et al (2019) Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. Eur J Cancer 109:36\u201350. https:\/\/doi.org\/10.1016\/j.ejca.2018.11.027","journal-title":"Eur J Cancer"},{"key":"6537_CR35","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/j.1476-5829.2010.00209.x","volume":"8","author":"JL Sottnik","year":"2010","unstructured":"Sottnik JL, Thamm DH (2010) Interleukin-11 receptor alpha is expressed on canine osteosarcoma. Vet Comp Oncol 8:96\u2013102. https:\/\/doi.org\/10.1111\/j.1476-5829.2010.00209.x","journal-title":"Vet Comp Oncol"},{"key":"6537_CR36","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-026-04015-5","author":"X Sun","year":"2026","unstructured":"Sun X, Qin Y, Ben Z et al (2026) Spatial targeting of sialic acid receptors for MRI\/BNCT-integrated boron drug-based antitumor therapy. Pharm Res. https:\/\/doi.org\/10.1007\/s11095-026-04015-5","journal-title":"Pharm Res"},{"key":"6537_CR37","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.jconrel.2025.01.060","volume":"380","author":"Y Sung","year":"2025","unstructured":"Sung Y, Choi Y, Kim ES, Ryu JH, Kwon IC (2025) Receptor-ligand interactions for optimized endocytosis in targeted therapies. J Control Release 380:524\u2013538. https:\/\/doi.org\/10.1016\/j.jconrel.2025.01.060","journal-title":"J Control Release"},{"key":"6537_CR38","doi-asserted-by":"publisher","first-page":"4449","DOI":"10.1088\/0031-9155\/60\/11\/4449","volume":"60","author":"F Taupin","year":"2015","unstructured":"Taupin F, Flaender M, Delorme R et al (2015) Gadolinium nanoparticles and contrast agent as radiation sensitizers. Phys Med Biol 60:4449\u20134464. https:\/\/doi.org\/10.1088\/0031-9155\/60\/11\/4449","journal-title":"Phys Med Biol"},{"key":"6537_CR39","doi-asserted-by":"publisher","first-page":"4004","DOI":"10.1002\/mp.14928","volume":"48","author":"KW Van Delinder","year":"2021","unstructured":"Van Delinder KW, Khan R, Gr\u00e4fe JL (2021) Radiobiological impact of gadolinium neutron capture from proton therapy and alternative neutron sources using TOPAS-nBio. Med Phys 48:4004\u20134016. https:\/\/doi.org\/10.1002\/mp.14928","journal-title":"Med Phys"},{"key":"6537_CR40","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1039\/C4CS00336E","volume":"44","author":"P Verwilst","year":"2015","unstructured":"Verwilst P, Park S, Yoon B, Kim JS (2015) Recent advances in Gd-chelate based bimodal optical\/MRI contrast agents. Chem Soc Rev 44:1791\u20131806. https:\/\/doi.org\/10.1039\/C4CS00336E","journal-title":"Chem Soc Rev"},{"key":"6537_CR41","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s00432-025-06136-7","volume":"151","author":"L Xie","year":"2025","unstructured":"Xie L, Qin J, Song C et al (2025) 157Gd-DOTA-PSMA as theranostic bio-gadolinium agent for prostate cancer targeted gadolinium neutron capture therapy. J Cancer Res Clin Oncol 151:93. https:\/\/doi.org\/10.1007\/s00432-025-06136-7","journal-title":"J Cancer Res Clin Oncol"},{"key":"6537_CR42","doi-asserted-by":"publisher","DOI":"10.1177\/10849785261426657","author":"L Zhang","year":"2026","unstructured":"Zhang L, Quan R, Huang H et al (2026) Boronophenylalanine-mediated boron neutron capture therapy confers selective killing of cervical cancer by exploiting DNA repair deficiency. Cancer Biother Radiopharm. https:\/\/doi.org\/10.1177\/10849785261426657","journal-title":"Cancer Biother Radiopharm"},{"key":"6537_CR43","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2025.5611","author":"X Zheng","year":"2025","unstructured":"Zheng X, Pan J, Lin D, Shao W (2025) L-type amino acid transporter 1 in enhancing boron neutron capture therapy: mechanisms, challenges and future directions (Review). Int J Mol Med. https:\/\/doi.org\/10.3892\/ijmm.2025.5611","journal-title":"Int J Mol Med"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-026-06537-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-026-06537-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-026-06537-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:49:55Z","timestamp":1787878195000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-026-06537-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":43,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["6537"],"URL":"https:\/\/doi.org\/10.1007\/s00432-026-06537-2","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"assertion":[{"value":"17 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"168"}}